Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Christopher Anzalone — FY2025 total compensation $9,029,861

Christopher Anzalone is President and Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (ARWR). The company reported total compensation of $9,029,861 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$981,046
Bonus$0
Stock awards$6,810,292
Option awards$0
Non-equity incentive plan$1,236,000
Pension and non-qualified deferred compensation$0
All other compensation$2,523
Total$9,029,861

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Arrowhead Pharmaceuticals, Inc. filed January 27, 2026, accession 0000879407-26-000019.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025President and Chief Executive Officer$981,046$0$6,810,292$0$1,236,000$0$2,523$9,029,861
FY2024President and Chief Executive Officer$951,012$0$10,319,000$0$1,152,000$0$1,461$12,423,473
FY2023President and Chief Executive Officer$902,522$0$8,314,056$0$700,000$0$1,515$9,918,093

Totals as disclosed in each year's own compensation disclosure for Arrowhead Pharmaceuticals, Inc..

03

Peer context

Peer-group chief executive median$9,512,640
Difference from that median$-482,779
Percentile within the disclosed peer group47th
Peers with a disclosed figure19

Medians and percentiles are computed across the peer group Arrowhead Pharmaceuticals, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of Arrowhead Pharmaceuticals, Inc.

Named executive officerRoleFY2025 total
Christopher Anzalone this pagePresident and Chief Executive Officer$9,029,861
Patrick O'BrienChief Operating Officer$3,030,195
James HamiltonChief Medical Officer$2,966,213
Kenneth MyszkowskiFormer Chief Financial Officer$2,660,161
Tracie OliverFormer Chief Commercial Officer$43,193

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Arrowhead Pharmaceuticals, Inc. compensation brief.

05

The company page

Christopher Anzalone's compensation sits inside Arrowhead Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Arrowhead Pharmaceuticals, Inc. (ARWR) compensation brief